Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Net Income towards Common Stockholders (2020 - 2025)

Oncology Institute (TOI) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$13.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 14.32% year-over-year to -$13.8 million, compared with a TTM value of -$61.2 million through Sep 2025, up 9.21%, and an annual FY2024 reading of -$53.0 million, up 21.91% over the prior year.
  • Net Income towards Common Stockholders was -$13.8 million for Q3 2025 at Oncology Institute, up from -$17.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$10.7 million, with a median of -$12.7 million recorded in 2024.
  • Peak annual rise in Net Income towards Common Stockholders hit 12766.67% in 2021, while the deepest fall reached 248350400.0% in 2021.
  • Year by year, Net Income towards Common Stockholders stood at -$9.9 million in 2021, then fell by 10.8% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then soared by 42.27% to -$10.8 million in 2024, then dropped by 27.53% to -$13.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for TOI at -$13.8 million in Q3 2025, -$17.0 million in Q2 2025, and -$19.6 million in Q1 2025.